Patents by Inventor Chikwendu Ibebunjo
Chikwendu Ibebunjo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240066132Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.Type: ApplicationFiled: July 14, 2023Publication date: February 29, 2024Inventors: David Weninger BARNES, Avirup BOSE, Alexandra Marshall BRUCE, Alokesh DUTTAROY, Chikwendu IBEBUNJO, Aaron KANTER, Louise Clare KIRMAN, Changgang LOU, Aimee Richardson USERA, Ken YAMADA, Jun YUAN, Frederic ZECRI
-
Patent number: 11180546Abstract: This invention is in the field of anti-transforming growth factor beta 2 (TGF-?2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-?2 isoform preferentially over the human TGF-?1 or TGF-?3 isoforms.Type: GrantFiled: February 17, 2017Date of Patent: November 23, 2021Assignee: NOVARTIS AGInventors: Chikwendu Ibebunjo, Carsten Jacobi, Angelika Meyer, Eveline Schaadt, Anne-Ulrike Trendelenburg, Olga Vladimirovna Mitina
-
Publication number: 20210000964Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.Type: ApplicationFiled: June 1, 2020Publication date: January 7, 2021Inventors: David Weninger BARNES, Avirup BOSE, Alexandra Marshall BRUCE, Alokesh DUTTAROY, Chikwendu IBEBUNJO, Aaron KANTER, Louise Clare KIRMAN, Changgang LOU, Aimee Richardson USERA, Ken YAMADA, Jun YUAN, Frederic ZECRI
-
Publication number: 20200362015Abstract: The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.Type: ApplicationFiled: February 26, 2020Publication date: November 19, 2020Inventors: Donglin GUO, Chikwendu IBEBUNJO
-
Patent number: 10654909Abstract: The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.Type: GrantFiled: December 2, 2015Date of Patent: May 19, 2020Assignee: Novartis AGInventors: Donglin Guo, Chikwendu Ibebunjo
-
Publication number: 20180326079Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.Type: ApplicationFiled: May 21, 2018Publication date: November 15, 2018Inventors: David Weninger BARNES, Avirup BOSE, Alexandra Marshall BRUCE, Alokesh DUTTAROY, Chikwendu IBEBUNJO, Aaron KANTER, Louise Clare KIRMAN, Changgang LOU, Aimee Richardson USERA, Ken YAMADA, Jun YUAN, Frederic ZECRI
-
Publication number: 20180037623Abstract: The present disclosure is directed to compositions and methods related to an alpha sKlotho variant or fragment, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795. The present disclosure also pertains to an alpha sKlotho polypeptide variant or fragment, having mutations at V563 and/or K795, wherein the polypeptide variant or fragment is full-length, or optionally 1 to up to about 20 amino acids have been deleted from the C-terminus. The present disclosure also pertains to fusion polypeptides comprising: (a) an alpha sKlotho, in which 1 to up to about 20 amino acids have been deleted from the C-terminus, optionally also having mutations at V563 and/or K795; (b) a linker; and (c) FGF23, optionally having a mutation at R179, C206 and/or C244, or (c) serum albumin.Type: ApplicationFiled: December 2, 2015Publication date: February 8, 2018Applicant: Novartis AGInventors: Donglin GUO, Chikwendu IBEBUNJO
-
Publication number: 20160030585Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.Type: ApplicationFiled: June 12, 2015Publication date: February 4, 2016Applicant: NOVARTIS AGInventors: David Weninger BARNES, Ken YAMADA, Chikwendu IBEBUNJO, Alokesh DUTTAROY, Louis Clare KIRMAN, Alexandra Marshall BRUCE, Aimee Richardson USERA, Frederic ZECRI, Jun YUAN, Changgang LOU, Aaron KANTER, Avirup BOSE
-
Publication number: 20110091455Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.Type: ApplicationFiled: August 26, 2010Publication date: April 21, 2011Applicants: AMGEN FREMONT INC., AGOURON PHARMACEUTICALS, INC.Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachwieja
-
Patent number: 7807159Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.Type: GrantFiled: April 24, 2006Date of Patent: October 5, 2010Assignees: Amgen Fremont Inc., Agouron Pharmaceuticals, Inc.Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachweija
-
Publication number: 20060263354Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.Type: ApplicationFiled: April 24, 2006Publication date: November 23, 2006Inventors: Eva Rose Chin, Larry Green, Chikwendu Ibebunjo, Philip Krasney, Junming Yie, Joseph Zachwieja